Abbvie Inc (ABBV) Stock Price, Quote & News

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 847 932 7900

Website: www.abbvie.com

Address:

1 North Waukegan Road, North Chicago, United States

JohnTrack Jan. 12 at 11:33 PM

$ABBV story drop, check it out!! https://www.rapidticker.com/news/abbv-abbvie-and-trump-administration-reach-d41cf7

0 · Reply

Luckyjs38 Jan. 12 at 10:58 PM

$ENVB i hope we see a settlement offer with $ABBV ? when paperwork to be submitted for stage 1 trails EB-003 ❤️

0 · Reply

StocktwitsNews Jan. 12 at 10:12 PM

Revolution Medicines Dismisses Merck, Abbvie Buyout Talks While Analyst Say It Is Worth More Than $32B $RVMD $ABBV $MRK https://stocktwits.com/news/equity/markets/revolution-medicines-dismisses-merck-abbvie-buyout-talks/cmUag2XR4Ex

0 · Reply

2dollartrader Jan. 12 at 5:35 PM

$ABBV when is this gonna pick up steam? Been doing nothing for months

0 · Reply

RedFeathers Jan. 12 at 5:24 PM

$IRWD ……. $ABBV shareholders 🤔 take a look 👇👇👇👇👇👇👇👇👇

0 · Reply

RedFeathers Jan. 12 at 5:08 PM

$IRWD $ABBV

0 · Reply

jim2359 Jan. 12 at 4:41 PM

$ABBV buy

1 · Reply

SuperGreenToday Jan. 12 at 4:25 PM

$ABBV Share Price: $219.82 Contract Selected: Feb 06, 2026 $220 Calls Buy Zone: $5.48 – $6.77 Target Zone: $8.88 – $10.86 Potential Upside: 53% ROI Time to Expiration: 24 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

taxplanr Jan. 12 at 3:57 PM

$BNTX $ABBV Johns Hopkins knows where the cures for cancer are coming from just like TikTokkers and Instagrammers Nice to see science trying to play catch up https://pure.johnshopkins.edu/en/publications/antiparasitic-mebendazole-shows-survival-benefit-in-2-preclinical-3/

0 · Reply

ZacksResearch Jan. 12 at 3:43 PM

$ABBV down 3% in a month — but selling here could be a mistake. ⚠️ The stock slipped amid takeover rumor denials, yet Skyrizi and Rinvoq momentum plus a deep pipeline are keeping the long-term case intact. Why holding still makes sense 👉 https://www.zacks.com/stock/news/2815553/abbvie-down-3-in-a-month-why-holding-the-stock-still-makes-sense?cid=sm-stocktwits-2-2815553-teaser-28411&ADID=SYND_STOCKTWITS_TWEET_2_2815553_TEASER_28411

0 · Reply

AbbVie and Trump Administration Reach Agreement to Improve Access and Affordability for Americans

Jan 12, 2026, 7:39 AM EST - 11 hours ago

AbbVie, RemeGen partner on experimental solid tumor treatment

Jan 12, 2026, 7:30 AM EST - 11 hours ago

AbbVie and RemeGen Announce Exclusive Licensing Agreement to Develop A Novel Bispecific Antibody for Advanced Solid Tumors

Jan 12, 2026, 6:00 AM EST - 12 hours ago

AbbVie to Acquire Arizona Manufacturing Facility, Further Strengthening Manufacturing Capabilities in the United States

WST

Jan 12, 2026, 6:00 AM EST - 12 hours ago

West Signs Agreement to Sell the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System to AbbVie

WST

Jan 12, 2026, 5:12 AM EST - 13 hours ago

Dividend Income: Lanny's November 2025 Summary

AFL CAT COF CVS CZNC EMR ETN

Jan 10, 2026, 9:30 AM EST - 2 days ago

MoneyShow's Best Investment Ideas For 2026: Part 1

ABR ACHR ARE ARES ARMN ASTS

Jan 8, 2026, 12:07 PM EST - 4 days ago

AbbVie: The Dividend Does Not Lie

Jan 8, 2026, 7:38 AM EST - 4 days ago

AbbVie Denies It's in Talks to Buy Revolution Medicines. Both Stocks Are Falling.

RVMD

Jan 7, 2026, 2:58 PM EST - 5 days ago

AbbVie in talks to buy biotech Revolution Medicines, WSJ reports

RVMD

Jan 7, 2026, 2:48 PM EST - 5 days ago

AbbVie Near Deal for Revolution Medicines

RVMD

Jan 7, 2026, 8:00 AM EST - 5 days ago

AbbVie to Host Full-Year and Fourth-Quarter 2025 Earnings Conference Call

Jan 6, 2026, 11:43 AM EST - 6 days ago

What Can Trigger A Breakout In Abbvie Stock?

Jan 6, 2026, 7:29 AM EST - 6 days ago

Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month

ARGX NBIX

Jan 5, 2026, 8:00 AM EST - 7 days ago

AbbVie to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 4, 2026, 9:04 AM EST - 8 days ago

AbbVie: Rocky Near-Term, Positive Long-Term

Jan 3, 2026, 7:30 AM EST - 9 days ago

My Most Important Warning To Dividend Investors For 2026

AM ARES CNI CPT ENB EPD EXR

Jan 1, 2026, 10:24 PM EST - 10 days ago

AbbVie: Solid Growth, Some Risks, And An Attractive Setup In 2026

Dec 31, 2025, 8:47 AM EST - 12 days ago

Best Dividend Aristocrats For January 2026

ABT ADM ADP AFL ALB AMCR AOS

Dec 28, 2025, 6:44 AM EST - 15 days ago

Best Dividend Kings: December 2025

ABM ABT ADM ADP AWR BDX BKH

Dec 19, 2025, 10:45 AM EST - 24 days ago

Trump to announce new drug-pricing deals later today

AMGN AZN BMY GILD LLY MRK NVO

Dec 17, 2025, 4:11 PM EST - 26 days ago

AbbVie, several other pharma companies near MFN deal with Trump, sources say

AMGN AZN BMY LLY NVS PFE

Dec 17, 2025, 2:17 PM EST - 26 days ago

Final Trades: Abbvie Inc, Microsoft, Netflix and Twilio Inc

MSFT NFLX TWLO

Dec 14, 2025, 11:30 PM EST - 4 weeks ago

AMG Frontier Small Cap Growth Fund: Q3 Sees Strong Outperformance Across Semiconductor Holdings

ALGT CGNX COHR EOLS INSP LTH MAT

Dec 10, 2025, 8:01 PM EST - 4 weeks ago

AbbVie: Unique Mix Of Growth And Value

Dec 8, 2025, 1:30 AM EST - 5 weeks ago

OSE Immunotherapeutics Announces Strategic Amendment to AbbVie's Partnership on ABBV-230 Development

Dec 3, 2025, 4:53 PM EST - 5 weeks ago

AbbVie Inc. (ABBV) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Dec 2, 2025, 8:15 AM EST - 5 weeks ago

AbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers

Dec 1, 2025, 5:55 AM EST - 6 weeks ago

AbbVie: Increased Outlook For 2025 And Expansions Merit Continued "Strong Buy" Rating

Nov 29, 2025, 8:02 AM EST - 6 weeks ago

Best Dividend Aristocrats For December 2025

ABT ADM ADP AFL ALB AMCR AOS

Nov 28, 2025, 7:01 AM EST - 6 weeks ago

SKYRIZI® (risankizumab) Receives Positive Reimbursement Recommendation by Canada's Drug Agency for Ulcerative Colitis and AbbVie Concludes Letter of Intent with the pan-Canadian Pharmaceutical Alliance

Nov 25, 2025, 9:30 AM EST - 6 weeks ago

AbbVie and adMare BioInnovations Foster Life Sciences Innovation with the Launch of the AbbVie Biotech Innovators Award in Quebec

Nov 24, 2025, 8:00 AM EST - 7 weeks ago

AbbVie to Present at the Piper Sandler 37th Annual Healthcare Conference

$AbbVie Announces U.S. FDA Approval of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma$

Nov 18, 2025, 12:47 PM EST - 7 weeks ago

AbbVie Announces U.S. FDA Approval of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma

Nov 18, 2025, 9:00 AM EST - 7 weeks ago

It's Best Time In 10 Years To Lock In Income: Our Picks

ADC AVGO DG ENB EPD FDX MSFT

Nov 18, 2025, 8:25 AM EST - 7 weeks ago

Global drugmakers rush to boost US presence as tariff threat looms

AMGN AZN BIIB GILD GSK JNJ LLY

Nov 14, 2025, 4:31 PM EST - 2 months ago

AbbVie Inc. (ABBV) Presents at 7th Annual Healthcare Symposium Transcript

Nov 14, 2025, 3:19 PM EST - 2 months ago

Biopharma companies have confidence in their ability to do deals: BMO's Evan Seigerman

AZN JNJ LLY MRK NVO PFE XLV

Nov 13, 2025, 8:30 AM EST - 2 months ago

AbbVie Announces 20 Recipients of Migraine Career Catalyst Award™

Nov 12, 2025, 3:06 PM EST - 2 months ago

AbbVie Shares Rise To Intraday High After Key Trading Signal

Nov 12, 2025, 8:30 AM EST - 2 months ago

Chiesi Group Enters into an Exclusive License Agreement with Aliada Therapeutics, a Wholly Owned Subsidiary of AbbVie, to Advance Blood-Brain Barrier-Crossing Platform Technology in Lysosomal Storage Disorders

Nov 12, 2025, 8:30 AM EST - 2 months ago

Allergan Aesthetics Unveils New Data at 2025 American Society for Dermatologic Surgery Annual Meeting Showcasing Transformative Innovation and Portfolio Excellence

Nov 11, 2025, 10:40 PM EST - 2 months ago

AbbVie Has Many Bullish Attributes (Technical Analysis)

Nov 8, 2025, 6:38 AM EST - 2 months ago

Healthcare Q3 Dividend Roundup: I Prefer AbbVie Over Pfizer

PFE

Nov 3, 2025, 9:58 AM EST - 2 months ago

Biotech is back. Here's why these rallying stocks belong in your portfolio now.

ALNY AMGN BMY LLY MBX MDGL MEDI

Nov 1, 2025, 11:15 PM EDT - 2 months ago

ADP, Snap-on Lead 14 Companies To Announce Annual Increases In First Half Of November

ADP AEP AIZ AOS ATO BDX BRO

Nov 1, 2025, 10:25 AM EDT - 2 months ago

Best Dividend Aristocrats For November 2025

ABT ADM ADP AMCR AOS ATO BDX

Oct 31, 2025, 3:56 PM EDT - 2 months ago

AbbVie Inc. (ABBV) Q3 2025 Earnings Call Transcript

Oct 31, 2025, 11:47 AM EDT - 2 months ago

AbbVie Raises 2025 Outlook Helped By Strong Immunology Growth, Boost Dividend

Oct 31, 2025, 10:39 AM EDT - 2 months ago

AbbVie: Why Q3 Confirms Its Immunology Dominance

JohnTrack Jan. 12 at 11:33 PM

$ABBV story drop, check it out!! https://www.rapidticker.com/news/abbv-abbvie-and-trump-administration-reach-d41cf7

0 · Reply

Luckyjs38 Jan. 12 at 10:58 PM

$ENVB i hope we see a settlement offer with $ABBV ? when paperwork to be submitted for stage 1 trails EB-003 ❤️

0 · Reply

StocktwitsNews Jan. 12 at 10:12 PM

0 · Reply

2dollartrader Jan. 12 at 5:35 PM

$ABBV when is this gonna pick up steam? Been doing nothing for months

0 · Reply

RedFeathers Jan. 12 at 5:24 PM

$IRWD ……. $ABBV shareholders 🤔 take a look 👇👇👇👇👇👇👇👇👇

0 · Reply

RedFeathers Jan. 12 at 5:08 PM

$IRWD $ABBV

0 · Reply

jim2359 Jan. 12 at 4:41 PM

$ABBV buy

1 · Reply

SuperGreenToday Jan. 12 at 4:25 PM

0 · Reply

taxplanr Jan. 12 at 3:57 PM

0 · Reply

ZacksResearch Jan. 12 at 3:43 PM

0 · Reply

taxplanr Jan. 12 at 3:40 PM

$ABBV has anyone compared the side effects of Ubrelvy and Qulipta high blood pressure -circulation problems in your fingers and toes -liver problems -kidney problems -Are pregnant or plan to become pregnant -Are breastfeeding or plan to breastfeed -Raynaud’s phenomenon to say Gammacor or Truvaga Plus from $ECOR which can also be used off label for like the rest of $ABBV approved drugs And PEMF causes apoptosis of cancer tumors

0 · Reply

taxplanr Jan. 12 at 3:25 PM

$ABBV the wave of people foregoing chemo for cancer is about to go parabolic the rest of their pipeline is vulnerable also https://makisw.substack.com/p/ivermectin-fenbendazole-dmso-cbd?utm_source=post-email-title&publication_id=1385328&post_id=184197670&utm_campaign=email-post-title&isFreemail=true&r=18m8lm&triedRedirect=true&utm_medium=email

0 · Reply

ZacksResearch Jan. 12 at 2:43 PM

$ABBV dips 3.2% amid takeover denial, but is it a buy-the-dip opportunity? 🤔 💊 Strong performance from Skyrizi & Rinvoq with combined sales of $18.5B in the first nine months of 2025 🌟 Expecting to surpass $25B target by 2025 📈 Neuroscience sales up 20.3% driven by Vyalev and migraine drugs Ubrelvy and Qulipta See why ABBV could still be a strong play in your portfolio 👉 https://www.zacks.com/stock/news/2815553/abbvie-down-3-in-a-month-why-holding-the-stock-still-makes-sense?cid=sm-stocktwits-2-2815553-body-28410&ADID=SYND_STOCKTWITS_TWEET_2_2815553_BODY_28410

0 · Reply

OpenOutcrier Jan. 12 at 1:49 PM

$ABBV (+0.2% pre) AbbVie to acquire West Pharmaceutical facility in Arizona for $175M; West to sell SmartDose 3.5mL manufacturing rights to AbbVie for $112.5M; AbbVie licenses cancer drug from RemeGen for $650 million upfront https://ooc.bz/l/89364

0 · Reply

MoneyGroupLLC Jan. 11 at 9:14 PM

Enter: $ABBV Calls Strike Price: $225 Expiry Date: FEB 06 2026 Buy in Price: $4.55 - $5.00 Sell Price: $6.96 Profit : +53% (Turn every $1 into $1.53) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/

0 · Reply

WaverVanir Jan. 11 at 1:59 PM

$ABBV Bearish setup developing 🐻 Multiple CHoCH signals at the premium zone ($226-243). Price rejected weak high and now testing key levels: ⚠️ Breaks $216 → confirms breakdown 🎯 Target: Equilibrium at $204.02 Structure: Premium zone rejection ✓ Lower highs forming after Oct peak RSI rolling over (51) — momentum fading Strong low sits at $170 if equilibrium fails to hold. VolanX flagged: PUT 75% conf | $223.93 → $211.35 target — WaverVanir International

0 · Reply

beeelaaal Jan. 11 at 1:44 PM

$VSTM $ABBV or $AMGN

0 · Reply

WaverVanir Jan. 11 at 1:41 PM

VolanX SWING scan complete ⚡ 34 signals found across market Top hits: 📈 $MELI — CALL 75% conf | Entry $2187 → Target $2375 | 1.5 R:R | 58% win 📈 $OTIS — CALL 75% | $89.89 → $93.62 | 1.5 R:R | 58% win 📉 $ABBV — PUT 75% | $223.93 → $211.35 | 1.5 R:R | 58% win 📈 $FXI — CALL 75% | $39.91 → $41.64 | 1.5 R:R | 58% win 📈 $CRWD — CALL 75% | $458.32 → $484.44 | 1.5 R:R | 66% win 28 CALLs | 6 PUTs | 21 high confidence (≥70%) | Avg conf: 70.1% Q/A welcome 👇 https://youtu.be/h_TjDA-zyfo?si=oMeLxwKZrtPM301B

0 · Reply

Gps_100X_ROI_Potential Jan. 11 at 10:44 AM

$SLS $ABBV $BMY $RHHBY

0 · Reply

WallStreetBuyDip Jan. 11 at 4:53 AM

$PFE trading at $25 with volume 33% below average, while $ABBV sitting at $220 with 6% above average volume. ABBV showing strength with a higher price level and increased volume - seems like a solid Healthcare sector play! Will these trends continue in the sector?

0 · Reply

Ashte Jan. 10 at 7:02 PM

$XLV $LLY $UNH $ISRG $ABBV

0 · Reply

JacoI3 Jan. 10 at 12:43 AM

$NVO Nobody takes advantage of America like America $LLY $ABBV $AMGN $MRK

1 · Reply

Market Cap	388.97B
Revenue (ttm)	56.33B
Net Income (ttm)	4.28B
EPS (ttm)	N/A
PE Ratio	23.29
Forward PE	15.55
Profit Margin	7.59%
Debt to Equity Ratio	-26.45

Volume	6,544,831
Avg Vol	6,024,820
Day's Range	N/A - N/A
Shares Out	1.77B
Stochastic %K	12%
Beta	0.36
Analysts	Strong Sell
Price Target	$245.44